Know Cancer

or
forgot password

Therapy of Late Chronic Phase Chronic Myelogenous Leukemia (CML) With High-Dose Gleevec (STI571)


Phase 2
15 Years
N/A
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Therapy of Late Chronic Phase Chronic Myelogenous Leukemia (CML) With High-Dose Gleevec (STI571)


Treatment: Imatinib mesylate is a new oral medication that blocks a protein that is
responsible for CML

Patients on this study will take 400 mg of imatinib twice daily (morning and evening). If
you have side effects, the dose may be lowered. If you are taking less than 800 mg of
imatinib, you can take your dose once per day or divided in two doses. Imatinib mesylate
should be taken with a large glass of water.

After completing 3 to 12 months of therapy, response to imatinib mesylate will be evaluated.
Treatment may be continued for up to 20 years, or as long as it is judged best to control
the leukemia.

Update June 2010:

Blood tests are recommended 2 times per year. Your doctor will discuss with you how often
you should have blood tests. Bone marrow will be done if your doctor thinks it is necessary
to check your disease. You must return to M. D. Anderson at least once every year. You may
not need a bone marrow test every visit, but you will have blood drawn to measure the amount
of disease you have. If the leukemia cannot be found for 2 years or longer on the blood
test called PCR which is done to measure the amount of disease you have, your doctor may
talk to you about stopping treatment with imatinib. If you and your doctor decide to stop
your therapy, you will have a blood test for PCR done every 3 to 6 months. You do not need
to return to M. D. Anderson to have this blood test done. You may have the blood taken by
your local doctor and mailed to M. D. Anderson. If the leukemia is found again by the PCR
blood test, your doctor may recommend that you restart treatment with imatinib. You may
decide to stay on treatment with imatinib even if your PCR blood test does not show any sign
of leukemia for 2 years or longer.

This is an investigational study. The FDA has authorized the use of imatinib mesylate for
patients with CML. It is the dose of imatinib mesylate being used that is investigational. A
total of 50 patients will take part in this study. All will be enrolled at M.D. Anderson.


Inclusion Criteria:



1. Patients age 15 years or older with a diagnosis of Ph-positive or Bcr-positive CML in
chronic phase CML. They should be in at least one of the categories below: A.
Patients must have received interferon alpha and: - Failed to achieve or lost a
hematologic complete remission(after 3 months of therapy with interferon), or -
Failed to achieve or lost a major cytogenetic remission, or - Failed to achieve or
lost a complete molecular remission (competitive quantitative PCR <0.05%), or - Were
intolerant to interferon B. Patients in late chronic phase (i.e., >/= 12 months from
diagnosis) who have not received treatment with interferon and: - Have high risk for
toxicity with IFN-A (e.g., age >/= 60 years), or - Refuse to use IFN-A

2. ECOG performance of 0-2.

3. Serum bilirubin less than 2mg%, serum creatinine less than 2mg%.

Exclusion Criteria:

1. - NYHA Class 3-4 heart disease; Pregnant or lactating females

2. Women of pregnancy potential must practice contraception

3. Patients in accelerated phase (except clonal evolution) or blastic phase are
excluded. - Patients with clonal evolution as their only criterion for accelerated
phase are eligible.

4. Inclusion of women and minorities: As per NIH policy, women and members of minorities
will be included in this protocol as they are referred in the CML population.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Cytogenetic CR Rate

Outcome Time Frame:

At 6 months

Safety Issue:

Yes

Principal Investigator

Jorge E Cortes, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The University Of MD Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

ID01-292

NCT ID:

NCT01092741

Start Date:

July 2001

Completion Date:

Related Keywords:

  • Leukemia
  • Leukemia
  • Gleevec
  • STI571
  • CML
  • Chronic Myelogenous Leukemia
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid, Chronic-Phase

Name

Location
The University Of MD Anderson Cancer Center Houston, Texas  77030